COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use
- ‘Cancer-Shattering’ Method Targets Non-Coding Sequences to Eradicate Brain Tumors
- What is HIV Post-Exposure Prophylaxis (PEP)?
- Moderna Team Detects No Uptake of mRNA-LNPs in Muscles at Injection Site
- Vitamin B5 Found to Promote Cancer Growth
- Harmful Chemical D5 Found in Common Hair Care Products
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
On May 12, the World Health Organization (WHO) announced that its COVID-19 Technology Access Pool (C-TAP) and Medicines Patent Pool (MPP) have reached a licensing agreement with the National Institutes of Health (NIH).
NIH awarded 11 COVID-19 patented technologies to the former in order to make them accessible to more companies and develop more commercial products that meet current and future public health needs.
These licenses are transparent, global and non-exclusive and allow pharmaceutical companies around the world to partner with MPP, C-TAP, and make these technologies accessible to people in low- and middle-income countries to help end the COVID-19 pandemic.
In most cases, the NIH does not collect royalties on licensed products from the 49 countries classified as least developed by the United Nations.
The 11 COVID-19 patented technologies in the agreement include the prefusion spike protein used in vaccine development, as well as other development, research, and diagnostic tools.
WHO COVID-19 Technology Access Pool
In May 2020, WHO and partners launched the COVID-19 Technology Access Pool (C-TAP) to facilitate timely, equitable and affordable access of COVID-19 health products by boosting their supply. C-TAP provides a global one-stop shop for developers of COVID-19 therapeutics, diagnostics, vaccines and other health products to share their intellectual property, knowledge, and data, with quality-assured manufacturers through public health-driven voluntary, non-exclusive and transparent licenses.
By sharing intellectual property and know-how through the pooling and these voluntary agreements, developers of COVID-19 health products can facilitate scale up production through multiple manufacturers that currently have untapped capacity to scale up production.
………
COVID drug patents: NIH MPP and WHO reached licensing agreement
(source:internet, reference only)
Disclaimer of medicaltrend.org
